19:39 IST
BSE
Other Announcement
Piramal Pharma Other Announcement
Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.
Piramal Pharma Ltd
- Share price
- ₹210.31
- Market cap
- ₹28,000 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -89.3×Sector 50.4×
- Promoter holding
- 34.80%-0.06% QoQ
- FII holding
- 12.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements
19:50 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.
14:28 IST
BSE
Other Announcement
Piramal Pharma Other Announcement
Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.
20:54 IST
NSE
Earnings Call
Piramal Pharma Investor Presentation: Key Takeaways
Piramal Pharma started FY27 with 17% revenue growth and 72% EBITDA expansion. Momentum was driven by CDMO recovery and power brands.
20:45 IST
NSE
Financial Results
Piramal Pharma Q1 FY27 Results: Net Loss of ₹69.4 Cr, Loss Narrows
Piramal Pharma Ltd reported revenue from operations of ₹2,270 Cr (+17.4% YoY) and a net loss of ₹69.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹69.4 Cr
21:10 IST
BSE
Financial Results
Piramal Pharma Q4 FY26 Results: Net Loss of ₹8.8 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,752 Cr (-0.1% YoY) and a net loss of ₹8.8 Cr for Q4 FY26.
- Key figure
- Net loss ₹8.8 Cr